<DOC>
	<DOC>NCT00736658</DOC>
	<brief_summary>This is a single centre, double-blind, randomised, parallel group, placebo controlled study to assess the safety, tolerability and pharmacokinetics of AZD1386 when given as multiple doses to 32 (24 healthy young and 8 healthy elderly) Japanese subjects. For young healthy subjects (aged ≥20 to ≤45 inclusive) 3 consecutive multiple ascending dose panels are planned. For elderly healthy subjects (aged ≥65 to≤80 inclusive) 1 multiple dose panel is planned.</brief_summary>
	<brief_title>AZD1386 Japanese Multiple Ascending Dosing Study</brief_title>
	<detailed_description />
	<mesh_term>Chronic Pain</mesh_term>
	<criteria>Healthy Japanese males or females young (≥20 to ≤45 years inclusive) or elderly (≥65 to ≤80 years inclusive). Female subjects must be surgically sterile or postmenopausal. Body Mass Index (BMI) of ≥19 to ≤ 27 kg/m2 and weight of ≥45 to ≤90 kg Clinically normal physical findings including heart rate &gt; 45 bpm and laboratory values and normal resting ECG History of somatic or psychiatric disease/condition, which may interfere with the objectives of the study as judged by the investigator A family history of short or long QT syndrome (SQTS) or sudden cardiac death (SCD) amongst first degree relatives Subjects with orthostatic hypotension defined as a decrease of ≥ 25mmHg systolic blood pressure and/or a decrease of ≥15mmHg diastolic blood pressure within 5 minutes when going from a supine to standing position Clinically significant illness or clinically relevant trauma within 2 weeks prior to the administration of the investigational product as judged by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Japanese</keyword>
	<keyword>MAD</keyword>
	<keyword>Multiple ascending dose</keyword>
	<keyword>Chronic pain</keyword>
</DOC>